ÂÜÀòÂÒÂ×

Frank Borriello has a diverse and extensive work experience in the biotechnology industry. Frank started their career as the Founder and Portfolio Manager at Biotech Horizons in 2005, where they managed portfolios and made investment decisions. From 2006 to 2008, they served as the Vice President at LifeTech Research.

In 2008, Frank joined Millennium Pharmaceuticals as the Director of Business Development, where they played a key role in identifying and evaluating potential partnerships and collaborations. Frank then moved on to Takeda Pharmaceuticals in 2012 as the Senior Director of Search and Evaluation, responsible for regional search and evaluation across therapeutic areas.

In 2013, Frank joined Shire Pharmaceuticals as the VP of Product Assessment, Strategic Planning, and Program Management. Frank led a multidisciplinary team to evaluate new product opportunities and potential in-licensing or M&A deals.

From 2014 to 2015, Frank worked at Baxter Bioscience as the Global Business Development Lead for Immunology and Gene Therapy. Frank facilitated the evaluation of assets for licensing or M&A and led cross-functional teams.

In 2015, Frank joined Baxalta as the Vice President and Head of Search and Evaluation, responsible for supporting the external innovation model of the company. Frank focused on finding and evaluating external assets for the Immunology and Gene Therapy Franchises.

From 2016 to 2018, Frank worked at Moerae Matrix, Inc. as the fractional Chief Business Officer (CBO). In this role, they contributed to strategic decision-making and business development activities.

In 2016, Frank also started their own biotechnology consulting firm, FB Biotech Consulting, where they provided consulting services to various clients.

Since 2016, Frank has been serving as the CEO of Alloplex Biotherapeutics Inc, a cellular therapeutics company based in Boston. Frank leads the company in the development of SUPLEXA cells, a PBMC-derived multicellular adoptive immunotherapy.

Overall, Frank Borriello has held various leadership and strategic roles in biotechnology companies, demonstrating their expertise in search and evaluation, business development, and product assessment.

Frank Borriello attended New York University from 1979 to 1983, where they obtained a Bachelor of Science degree in Chemistry. Following this, they pursued further education at the Albert Einstein College of Medicine from 1983 to 1991, earning both a Doctor of Medicine (MD) and a Doctor of Philosophy (PhD) degree. At the Albert Einstein College of Medicine, their field of study focused on Immunology and Cell Biology.